Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4873-4882

  Kodela, Ravinder ^a   Nath, Niharika ^b   Chattopadhyay, Mitali ^a   Enesbitt, Diandra ^a   Velázquez Martínez, Carlos A ^c   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Apoptosis; Cell cycle; Chemoprevention; NF B; Nonsteroidal anti inflammatory drugs; Thioredoxin reductase; Xenograft

Indexed keywords

HYDROGEN SULFIDE RELEASING NAPROXEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDROGEN SULFIDE; THIOREDOXIN REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HT-29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME FACTOR; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; HYDROGEN SULFIDE; MALE; MICE, NUDE; NAPROXEN; NF-KAPPA B; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940055970     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S91116     Document Type: Article

References (41)

1. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159:(2):161–166.
2. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002;3(3):166–174.
3. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4(1):29–42.
4. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the pre­vention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–884.
5. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2010;14(32):1–206.
6. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of com­plications. Am J Med. 1999;107(6A):3S–8S.
7. Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2012;83(6):723–732.
8. Chattopadhyay M, Kodela R, Nath N, et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012;83(6):715–722.
9. Chattopadhyay M, Kodela R, Nath N, et al. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 2012;83(6):733–740.
10. Kashfi K, Olson KR. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol. 2013;85(5):689–703.
11. Wallace JL, Dicay M, McKnight W, Martin GR. Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 2007;21(14):4070–4076.
12. Wallace JL, Ferraz JG, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal. 2012;17(1):58–67.
13. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med. 2007;42(5):706–719.
14. Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci. 2007;28(10):501–505.
15. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010;159(6):1236–1246.
16. Fiorucci S, Orlandi S, Mencarelli A, et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol. 2007;150(8):996–1002.
17. Elsheikh W, Blackler RW, Flannigan KL, Wallace JL. Enhanced chemo­preventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide. 2014;41:131–137.
18. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001;159(2):387–397.
19. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death – a new approach to cancer therapy. J Clin Invest. 2005;115(10):2625–2632.
20. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–310.
21. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010;10(4):369–373.
22. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12(8):715–723.
23. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011;13(1):11–22.
24. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.
25. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17(7):3629–3639.
26. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100(12):2952–2960.
27. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000;97(15):8542–8547.
28. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 2001;61(9):3810–3818.
29. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery. 2001;130(2):143–150.
30. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285–296.
31. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr.. A requirement for NF-kappaB activation in Bcr-Abl-mediated trans­formation. Genes Dev. 1998;12(7):968–981.
32. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107(3):241–246.
33. Mustacich D, Powis G. Thioredoxin reductase. Biochem J. 2000;346 Pt 1:1–8.
34. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16(6):420–426.
35. Zhao F, Yan J, Deng S, et al. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett. 2006;236(1):46–53.
36. Ouyang N, Williams JL, Tsioulias GJ, et al. Nitric oxide-donating aspirin pre­vents pancreatic cancer in a hamster tumor model. Cancer Res. 2006;66(8):4503–4511.
37. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280–288.
38. Ueno M, Masutani H, Arai RJ, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 1999;274(50):35809–35815.
39. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin reg­ulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992;20(15):3821–3830.
40. Bannister AJ, Cook A, Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene. 1991;6(7):1243–1250.
41. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012;7(4):e35196.